Astrocyte Pharmaceuticals
Astrocyte Pharmaceuticals: Innovating neuroprotective strategies through small molecule medicines.
Founded
2014Astrocyte Pharmaceuticals: Innovating neuroprotective strategies through small molecule medicines.
astrocytepharma.comCrawled Oct 16, 2026
Dr. Wright joined Astrocyte Pharmaceutical’s Scientific Advisory Board in October 2015. Wright is an emergency medicine chair and professor and directs Emergency Neurosciences at Emory University’s School of Medicine, focusing on therapies for traumatic brain injury and stroke.
Dr. Lechleiter is a co-founder and advisor of Astrocyte Pharmaceuticals and a professor at the University of Texas Health Science Center at San Antonio. His research investigates mechanisms of protection during ischemic stress, acute brain injury, and aging.
Dr. Saver joined Astrocyte Pharmaceutical’s Scientific Advisory Board in December 2018 and chairs its Clinical Advisory Board. He has directed the UCLA Stroke Unit since 1995 and is Professor and SA Vice-Chair of Neurology at the David Geffen School of Medicine at UCLA.
Mr. Arnold joined Astrocyte Pharmaceuticals’ Board of Directors in March 2017. He has 45 years of life science industry experience, including as CEO of four companies and an angel investor in seven companies with successful exits, and is President of Arnold Strategies, LLC.
Astrocyte Pharmaceuticals Inc. is headquartered in Groton, CT, and has an additional location in Cambridge, MA. It lists addresses at 93 Shennecossett Road, Groton, CT 06340, and 245 First Street, Suite 1800, Cambridge, MA 02142.
Astrocyte Pharmaceuticals is developing neuroprotection therapies for traumatic brain injuries (TBI), concussions, stroke, and neurodegenerative disorders.
Astrocyte’s privacy policy applies to astrocytepharma.com and covers information it may collect while operating the website. It states a commitment to protecting personally identifiable information provided through the site.